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Edited by Christian GriesingerAbstract The structure of human cytosolic thymidine kinase in
complex with its feedback inhibitor 2 0-deoxythymidine-5 0-tri-
phosphate was determined. This structure is the ﬁrst representa-
tive of the type II thymidine kinases found in several pathogens.
The structure deviates strongly from the known structures of
type I thymidine kinases such as the Herpes simplex enzyme.
It contains a zinc-binding domain with four cysteines complexing
a structural zinc ion. Interestingly, the backbone atoms of the
type II enzyme bind thymine via hydrogen-bonds, in contrast
to type I, where side chains are involved. This results in a spec-
iﬁcity diﬀerence exploited for antiviral therapy. The presented
structure will foster the development of new drugs and prodrugs
for numerous therapeutic applications.
 2005 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Using ATP, thymidine kinases catalyze the phosphorylation
of 2 0-deoxythymidine (dT) within the so-called pyrimidine sal-
vage-pathway. These kinases have been classiﬁed into type I
(long) and type II (short) subfamilies. The human cytosolic en-
zyme (hTK1) belongs to the type II while the Herpes simplex
virus 1 enzyme, whose structure is known, represents type I.
hTK1 is highly speciﬁc accepting only dT-analogs with re-
stricted changes in the sugar moiety [1]. In contrast, the sub-
strate speciﬁcity of type I subfamily is rather broad [2]. This
diﬀerence in speciﬁcity is the basic principle for the selectivity
of the established antiviral therapy using aciclovir and its
derivatives [3].
The type II thymidine kinases (TK) show very low sequence
similarity with the type I enzymes and other established nucle-
oside kinases rendering model building virtually impossible.
They occur in many diﬀerent organisms like bacteria (Staphy-
lococcus aureus, Bacillus anthracis, Mycoplasma pneumoniae),
eukaryotes (Leishmania major, Trypanosoma brucei) andAbbreviations: hTK1, human cytosolic thymidine kinase; dT, 2 0-
deoxythymidine; dTTP, 20-deoxythymidine-50-triphosphate; MAD,
multi-wavelength anomalous diﬀraction
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doi:10.1016/j.febslet.2005.01.034viruses (Cowpox, Vaccinia, Variola, Swinepox) that are likely
targets for therapeutic intervention. We suggest that the struc-
ture of hTK1 allows to produce reasonably accurate models of
the thymidine kinases of these organisms such that drugs and
prodrugs can be developed. The ability of type II TK of acti-
vating prodrugs is already documented for HIV therapy. Here,
hTK1 activates the prodrug 3 0-azido-2 0,3 0-dideoxy-thymidine
(AZT) that, in its triphosphorylated form, becomes an inhibi-
tor of the HIV reverse transcriptase.
Circumventing the cell growth inhibitory eﬀect of chemother-
apeutics like methotrexate that interfere with the pyrimidine
biosynthesis pathway, tumor cells use the pyrimidine salvage
pathway to continue proliferation [4]. This may be prevented
by adding hTK1 inhibitors as adjuvant for chemotherapeutics.
Such inhibitors can now be designed in the light of the known
structure since the missing structural information on type II en-
zymes prevented their development so far. Moreover, hTK1
has been used for the localization of tumors and metastasis with
positron emission tomography (PET) in combination with 18F-
labeled dT [5–7]. This PET tracer is taken up by highly prolif-
erating cells that show an increased hTK1 activity. It is then
phosphorylated accumulating a PET signal to be used for tu-
mor localization. Although, 18F-labeled dT has been used in
patients some problems related to liver accumulation and low
blood-brain barrier passage have been observed [7]. Thus, there
is a need for improved PET tracers for hTK1 and these can now
be ameliorated in a directed manner.
Herpes viral thymidine kinase is presently used as suicide
gene in therapies based on stem cell transplantation to control
them in case of adverse eﬀects such as graft versus host disease
[8,9]. Unfortunately, immunogenic epitopes of the Herpes en-
zyme are presented at the cell surface causing elimination by
T-cells and thus loss of the transplanted stem cells resulting
in treatment failure. Now the structure of hTK1 allows engi-
neering toward a non-immunogenic human suicide gene to re-
place the Herpes enzyme overcoming the encountered
problems [10]. Taken together the presented structure concerns
an enzyme that is deeply involved in various modern therapeu-
tic approaches.2. Materials and methods
2.1. Crystallization
The hTK1 was cloned as N-terminal thrombin-cleavable His6-
tagged fusion protein missing 14 amino acids of the N-terminus
and 40 amino acids of the C-terminus of the wild type hTK1 se-
quence of 234 amino acids (this construct is further on calledblished by Elsevier B.V. All rights reserved.
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type sequence plus an N-terminal extension of 15 residues contain-
ing a His6-tag, was eluted from gel ﬁltration column at a concentra-
tion of approximate 7 mg/ml with a buﬀer containing 5 mM Tris at
pH 7.2, 10 mM NaCl and 10 mM DTT. For protein crystallization
we used the hanging drop method at 23 C. Initial conditions for
crystallization were found using Crystal screen Cryo no. 40 (Hamp-
ton Research). The protein solution was mixed in a 1:1 ratio with
crystallization buﬀer (0.095 mM tri-sodium citrate, pH 5.5, 12%
PEG 4000, 10% isopropanol) to set up drops of 6 ll. The reservoir
contained 500 ll of crystallization buﬀer.
Crystals appeared after 3 days and grew within 3 days to sizes of
about 300 · 150 · 70 lm3 and diﬀracted to 1.7 A˚ resolution. They
belong to space group C2 with a = 157.5 A˚, b = 122.9 A˚,
c = 115.3 A˚, a = c = 90 and b = 130. The asymmetric unit contains
8 monomers forming two tetramers. The solvent content is 48%. For
X-ray data collection the crystals were cryo-protected using crystal-
lization buﬀer with additional 30% glycerol soaking for one minute.
The crystals diﬀract up to 1.7 A˚ resolution and are stable under X-
radiation from beamline X06SA at Swiss Light Source (Villigen/
CH).
2.2. Data collection, phase determination and reﬁnement
Three datasets were collected from two crystals. A ﬂuorescence
scan from one crystal was performed and data were collected at
two wavelengths (k = 1.2776 A˚ (zinc edge) and 0.9196 A˚). The data
processing was performed with the program XDS [11]. These data
sets were used for multi-wavelength anomalous diﬀraction (MAD)
phasing. The zinc coordinates were determined with program CNS
[12]. Initial two wavelength MAD phases to 4 A˚ were obtained with
SHARP [13] and extended to 1.83 A˚ by 8-fold NCS averaging, sol-
vent ﬂattening and histogram matching implemented in RESOLVE
[14] using the third data set (k = 0.9793 A˚) collected from the second
crystal. An initial model was obtained with RESOLVE, which was
subsequently rebuilt and reﬁned with XFIT [15] and REFMAC
[16], respectively. Model reﬁnement was started using NCS re-
straints, which were stepwise released and ﬁnally omitted. Water
molecules were introduced using ARP_WATERS [16] when the R-
factor reached 20%. Reﬁnement results were checked with PRO-
CHECK [17] and WHATCHECK [18]. Coordinates and structure
factors have been deposited in the Brookhaven Protein Data Bank
(Accession code 1w4r). The ﬁgures were produced with POVScript+
[19]. For secondary structure assignment DSSP [20] was used. The
B-factor plot was calculated with BAVERAGE [16] and the density
correlation was done with the program OVERLAPMAP [21]. The
numbering of the hTK1 [EC 2.7.1.21] sequence corresponds to the
hTK1 SwissProt entry P04183.Fig. 1. Representative sequence alignment of hTK1 (SwissProt ID P04183
Leishmania major (TrEMBL ID Q9N9I4) and Mycoplasma pneumoniae (P75
dots. Residues which could be structurally aligned with Herpes viral thymid
yellow colored parts of Fig. 2B. Residues given in lower case were not mod3. Results and discussion
Wild type hTK1 has 234 amino acids and forms a tetra-
mer in solution [1]. The crystallized fragment consists of res-
idues 15–194 plus an N-terminal extension of 15 residues
containing a His6-tag. This truncated form of hTK1 was de-
signed to avoid protein precipitation during puriﬁcation and
corresponds in length to Vaccinia Virus TK (Fig. 1) that
possess one of the shortest sequence among the type II
TK. In contrast to the wild type hTK1, this truncated form
is a dimer in solution (Supplementary material Fig. S6).
Nevertheless, it conserved an intact thymidine kinase activity
(Supplementary material Fig. S7) with a Km value for dT of
0.8 ± 0.3 lM that is comparable to previously published Km
value of 0.5 lM for the wild type enzyme [22]. Similar to
wild type enzyme, this truncated form of hTK1 is also inhib-
ited by deoxythymidine-5 0-triphosphate (dTTP) [23]. The en-
zyme (in complex with dTTP) crystallized in space group C2
with eight subunits per crystallographic asymmetric unit that
form two D2-symmetric tetramers (Fig. 2). Subunit A has
the continuous chain from residues 18 to 191, whereas the
other subunits have insuﬃcient density for ﬂexible residues
62–75. The structure was determined using zinc ion anoma-
lous diﬀraction and reﬁned to 1.83 A˚ resolution to good
quality (Table 1). During the reﬁnement a strong density ap-
peared within a putative binding cavity in each subunit
which was eventually identiﬁed as the feedback inhibitor
dTTP (Fig. 3). Since dTTP was not present in the protein
puriﬁcation process or crystallization set up we assume that
it originates from E.coli metabolism. The enzymatic activity
of the expressed hTK1 in E.coli was most probably silenced
by dTTP feedback inhibition preventing cell toxic eﬀects and
allowing a sustained expression of soluble protein.
The core of the protein contains a six stranded parallel b-
sheet surrounded by ﬁve a- and four 310-helices (Figs. 2 and
4). In the chainfold of the enzyme four central b-strands
with the P-loop and one connecting helix can be superim-
posed on other nucleoside and nucleotide kinases [24–26],
while the rest of the main chain is substantially diﬀerent.) with other type II thymidine kinases from Vaccinia virus (O57203),
070). Identical residues are highlighted by stars, conserved residues by
ine kinase (PDB-code 1VTK) are underlined. They correspond to the
eled in hTK1 because of lacking density.
Fig. 2. Stereoview of hTK1 in complex with the feedback inhibitor dTTP. (A) Subunits A–D of the D2-symmetric tetramer are shown in orange,
cyan, yellow and green. The inhibitor dTTP is shown as ball and stick model (main conformation only). (B) Subunits A with modeled substrate ADP
as taken from a superimposition with other nucleoside/nucleotide kinases [28]. This superposition is based on the yellow parts of the polypeptide
consisting of four central b-strands with P-loop and one helix. The real position of the adenine of the ADP/ATP diﬀers slightly avoiding the clash
with the blue a-helix 1 from the neighbouring subunit. Secondary structure elements have been assigned by the program DSSP [20], a-helices and
b-strands are numbered in black, 310 helices are depicted with grey numbers. (C) The zinc-binding domain consists of the residues 150 (N) to 191 (C).
The zinc ion is complexed by four cysteine side chains namely Cys 153, 156, 185 and 188.
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2. Subunits A and B (as well as C–D, E–F, and G–H) form
a dimer at the long helix a1 (Fig. 2).The Zinc binding domain spans from residues 150 to 191.
The metal binding motif formed by cysteines 153, 156, 185
and 188 accommodates a zinc ion (Fig. 2C), which was ﬁrst
Table 1
Data collection and reﬁnement statistics
Data set dTTP:hTK1
Diﬀraction dataa
X-ray source X06SA (SLS Villigen/CH)
Unit cell dimensions (A˚) a = 157.5; b = 122.9; c = 115.3;
a = c = 90; b = 130.0
Resolution range (A˚) 20.0–1.83 (1.95–1.83)
Completeness (%) 99.5 (99.8)
Multiplicity 7.1 (7.1)
Unique reﬂections 147503 (25536)
Rsym-I (%) 8.4 (39.4)
I/r 17.1 (7.9)
Space group C2
Protomers per ASU 8
Wavelength (A˚) 0.97934
Reﬁnement and ﬁnal model
Rcryst/Rfree (%) 15.9 /18.9
Number of reﬂections in
working set
140080 (10345)














Rmsd from ideal geometry
Bond lengths (A˚) 0.016
Angles () 1.7
Ramachandran angles:
Favored regions (%) 93.8
Allowed regions (%) 6.2
aThe data were collected at 100 K. Values in parentheses are for the
outermost shell.
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shown). Anomalous diﬀraction at the K-zinc edge was used
for phase determination. Two cysteines are positioned before
b-strand 7 and the other two after b-strand 8. Together with
the antiparallel b-sheet formed by b-strand 7 and b-strand 8,
the zinc bound to the cysteines seems to be crucial for the for-
mation of the nucleoside binding site by stabilizing the confor-
mation of the rather ﬂexible loop (Leu166-Lys180) (Fig. 4),
which is involved in nucleoside binding (Figs. 2c, 3). This cys-
teine motif –Cys–X–X–Cys–Z–Cys–X–X–Cys– is conserved
for all enzymes of the type II subfamily as shown in the align-
ment (Fig. 1). In M. pneumoniae and S. aureus, however, the
last cysteine is replaced by a histidine. The number of residues
between the second and third cysteine is generally Z = 28 be-
sides L. major and M. pneumoniae with Z = 29 and S. aureus
and B. anthracis with Z = 34. The metal binding motif resem-
bles the zinc binding motif of adenylate kinases of gram-posi-
tive bacteria [27].
The active center of the enzyme is deﬁned by the bound feed-
back inhibitor dTTP observed in each of the subunits (Fig.2A). Two slightly diﬀerent binding conformations were found
with an occupancy of 40% and 60%, respectively (Fig. 3A).
Apart from the b-phosphate, that assumes two opposite posi-
tions in space, the two conformations are almost superimposed
as shown in Fig. 3A. Presumably, the b-phosphate is at the
place where the catalytic phosphoryl group transfer occurs as
observed with adenylate kinase. Therefore a major mobility
may expected explaining the observed two diﬀerent position
of the b-phosphate. Thymine is tied by a hydrogen bond net-
work to the polypeptide backbone namely O4 with amide N
of Phe128, O2 with amide N of Val174 and N3 with carbonyl
oxygen of Val172. Moreover, it stacks between Phe101,
Phe133 and Tyr181 (Fig. 3B). The C5 of thymine contacts
Thr163. The ribose moiety of dTTP is depicted in its South
(3 0-exo/2 0-endo) conformation and held in a hydrophobic envi-
ronment formed by Met28, Phe101 and Leu124 and stabilized
by hydrogen bonds. The c-phosphoryl group of dTTP binds
the P-loop with its sequence ﬁngerprint –G–P–M–F–S–G–K–
S– which is highly conserved for the type II subfamily. Its se-
quence diﬀers slightly from the P-loop of the type I enzymes
[24] while maintaining the same function. The P-loop (Gly26
to Ser33) forms a giant anion hole that binds the b-phosphate
of ATP tightly in order to transfer the c-phosphoryl group
onto dT in the catalyzed reaction [28]. The catalytic residues
Lys32 of the P-loop, that is assumed to be responsible for
the transfer of the c-phosphate from ATP to 5 0-OH-group of
dT, and Glu98, that acts as a base accepting the proton of
the 5 0-OH-group of dT in the ester forming reaction, are struc-
turally conserved and present in all nucleoside/nucleotide
kinases [25].
In the active center of hTK1 a hydrogen bonding network
binds thymine to the backbone of the protein. This binding
mode of thymine is in contrast to the one observed within
the type I enzymes [29] and most other nucleoside/nucleotide
kinases [30–32] which bind it via side chains. In the Herpes
type I thymidine kinase Gln125 forms two hydrogen bonds
to thymine. This glutamine is able to adapt to the diﬀerent
substrates like ganciclovir and 2 0-deoxycytidine and their spe-
ciﬁc hydrogen-bond donor acceptor pattern by ﬂipping its
amide [33]. Such an adaptation is clearly not possible if the
backbone of the protein is involved as in hTK1. In the case
of 2 0-deoxycytidine that has a comparable size to dT, the
presence of the amino group with hydrogen-bond donor
character at the place of the O4 (hydrogen-bond acceptor)
of dT causes repulsion with the amide N of Phe128. The aro-
matic residues Phe101, Phe133 and Tyr181 are squeezing the
base from opposite directions. This arrangement is similar to
Phe96 and Phe137 of human deoxycytidine kinase but diﬀers
from the stacking of Met128 and Tyr172 in the Herpes en-
zyme [25]. These ﬁndings explain the diﬀerence in substrate
acceptance observed between the nucleoside/nucleotide ki-
nases. Substrate acceptance decreases from the Herpes TK
having the broadest one, over human deoxycytidine kinase,
human uridine cytidine kinase [32] to hTK1 with the narrow-
est one [25].
This major diﬀerence in binding mode among type I and II
subfamilies accounts for the narrow substrate acceptance and
higher speciﬁcity of hTK1 exploited for selective antiviral ther-
apy. Furthermore, Thr163 points directly towards the C5 of
the base restricting additionally the space availability and leav-
ing no space for modiﬁcations at this position compared to the
Herpes enzyme. This explains the rejection of 5-bromovinylde-
Fig. 3. Stereoview of the active center of hTK1. Water molecules are red balls, hydrogen bonds are dashed lines. (A) Bound feedback inhibitor dTTP
with hydrogen bonding network. The conformation of dTTP in its two binding modes was derived from the Fo–Fc omit electron density map here
contoured at 3r (green). The 40% binding mode is shown in a semi transparent mode. (B) The nucleotide is bound by the tight interactions with
protein residues. Hydrogen bonds to main chain atoms and stacking of the pyrimidine ring between Phe101, Phe133 and Tyr181 are responsible for
the high substrate speciﬁcity.
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tion of the ribose form a cleft between Asp58 and Ile175. This
allows the accommodation of bulkier groups replacing the 3 0-
hydroxyl as for example the azido moiety of the prodrug AZT
that is accepted as a substrate.
The observed structure suggests that Glu98 acts as a base
accepting the proton of the 5 0-OH-group of dT in the ester
forming reaction corresponding to Glu83 of the Herpes en-
zyme [29]. Arg60 ﬁxes the phosphate of the product dTMP
which is at the position of the a-phosphate of dTTP in the
reported structure. The position of the b-phosphate of dTTP
corresponds to the c-phosphate position of ATP which is
transferred to dT. In the Herpes thymidine kinase like in
numerous other nucleoside/nucleotide kinases the adenine
of ATP is hydrogen bonded to the backbone oxygen of
Gln331 situated at the N-terminus of an a-helix and inter-acts with Arg216 in a common stacking mode from one side
while the other side is exposed to solvent. In hTK1 the helix
binding the adenine moiety of ATP is missing in the mono-
mer of hTK1. However a corresponding helix is found at
the dimer interface between subunits A and B as well as
C and D shown in Fig. 2B. This helix contains Arg41 in
a suitable position to interact with the adenine. This indi-
cates further that subunits A and B together are constituting
a canonical active site, whereas subunits B and C do not
complement each other. Thus, the dimer A–B is most likely
the physiologically relevant one. This is in agreement with
the fact that the truncated form of hTK1 is a dimer in solu-
tion and is catalytically fully active (Supplementary material
Fig. S6 and Fig. S7). Catalytic activity cannot be expected
from the alternative dimer B–C although it harbors a
slightly larger interface.
Fig. 4. B-factor plot of the eight subunits of the reported hTK1 structure. The map correlation is depicted on the right side of the diagram. High
mobility of some residues leads to lacking parts in the structure. The line on top shows the secondary structure assignment as given by the program
DSSP [20]. The b-sheets and helices are displayed as arrows and tubes, respectively and labeled.
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pathogens indicates that rather accurate models can be pro-
duced because of a high homology. Nevertheless, the binding
site may slightly diﬀer because some of the residues involved
in van der Waals contacts to thymidine are only partially con-
served (Fig. 1). The structural knowledge on these diﬀerences
can be exploited to generate new ideas for the synthesis of
modiﬁed nucleosides towards the development of pathogen-
speciﬁc prodrugs. The structure of hTK1 indicates that it is
possible to add bulkier groups at the 3 0-position of the sugar
and/or at the C5-position of the base and that blocking the
sugars in the North (2 0-exo/3 0-endo) or South (3 0-exo/2 0-endo)
conformation is suitable for achieving selectivity towards the
TK of the pathogens [35]. The substrate speciﬁcity of hTK1
may be broadened by mutating residues surrounding the ribose
so that prodrugs with increased modiﬁcations at the sugar
mimicking moiety may be processed [35] and in general by
increasing space availability within the binding site. A ﬁrst
example of mutation is represented by Vaccinia Virus TK
(VVTK). In VVTK, Thr163 of hTK1 is replaced by Ser
(Ser148) while all other amino acids involved in dT binding
are conserved (Fig. 1). In contrast to hTK1 [35], VVTK is able
to phosphorylate (south)-methanocarbathymidine (Supple-
mentary material Fig. S8). For the design of hTK1 inhibitors,
the structural knowledge around the 5 0 position of dT and
around the phosphate of dTMP can be exploited to confer
favorable pharmacodynamic and pharmacokinetic characteris-
tics. The cleft near the 3 0-position of the ribose is the most
favorable region for inserting bulkier groups in novel PET
tracers complementing 18F-labeled dT. Unambiguously, diﬀer-
ent pharmaceutical ﬁelds of application will proﬁt from the
structural insights revealed by the presented structure of
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